Company Updates covers news from Brilliant Blue Biosciences. Research & Industry News highlights relevant developments published by external sources, summarised and attributed to them.
The FDA has outlined steps drugmakers can take to seek regulatory approval for gene editing medicines tailored to fix a single person's disease-causing mutation. The announcement is part of an ongoing ...
Source: Endpoints News
Read more →The plan builds on recent FDA moves to speed "personalized" treatments by offering an approval framework for therapies benefiting different subsets of patients with the same disease.
Source: BioPharma Dive
Read more →A Hiroshima University researcher contends that Japan's newly enacted law regulating human genome-edited embryos and germ cells marks a significant advance in the governance of reproductive genome editing.
Source: Phys.org
Read more →LANCASTER, PA — This spring, Lorraine and Mark Martin, a Mennonite family with a tax business, adopted a stubby-legged cow named Royal Lite. Lorraine, Mark and Royal Lite all have one thing in common: They ...
Source: Endpoints News
Read more →Therapy pioneered by biotechnology Chinese firm HuidaGene showed promise in animals but caused a fatal reaction in a child.
Source: Nature
Read more →University of Missouri researchers have created rice plants that resist bacterial blight, a devastating disease that threatens one of the world's most important food crops. The advance could help farmers in parts of Asia and Africa, where the disease can destroy harvests and threaten livelihoods.
Source: Phys.org
Read more →Rare disease advocates applauded the FDA's move to speed access to treatments.
Source: STAT
Read more →Last year, U.K. gene therapy startup Bloomsbury Genetic Therapies announced it was shutting down after dosing just one patient. Now, a nonprofit is resurrecting its lead program:
Source: STAT
Read more →Adding a personalized mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, according to results from the phase 3 INTerpath-001 trial presented at the ESMO Congress 2026.
Source: News-Medical
Read more →Human cells hold about two meters (6.6 feet) of DNA, folded and compacted to fit inside a nucleus. That packing is essential for life, but it creates a problem for scientists. Some of the genes that control a cell's identity are buried so deep in tightly packed DNA that gene-targeting tools such as CRISPR activation, or CRISPRa, struggle to reach them.
Source: Phys.org
Read more →A new AI-based tool identifies potential microRNA binding sites across circular RNA molecules, including regions conventional linear sequence analysis can miss, advancing research into gene regulation.
Source: Nanowerk
Read more →Long-awaited results from phase III trial show huge benefits for treatment-resistant melanoma.
Source: Nature
Read more →We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.
